Staying Vigilant for Immunocompromised Patients: Insights from a COVID-19 Expert Working Group

Missed us at IDWeek? We've provided our symposium On-Demand!

Though COVID-19 has been decreasing in its severity over the last several months, it is still a significant threat to immunocompromised people, such as those with cancer, transplant recipients, or those taking B-cell–depleting therapies. Anti-SARS-COV-2 monoclonal antibodies have been effective as both prophylaxis and treatment, though their efficacy depends on currently circulating variants. As new monoclonal antibodies continue in development, it is critical that clinicians are prepared to implement new approvals into practice. Drs Eric Daar, Brinda Emu, and Roger Bedimo debate and discuss implications of COVID-19 for immunocompromised patients, current status of COVID-19, anti-SARS-CoV-2 monoclonal antibodies as proof of concept for treatment and prophylaxis, and current guidelines for immunocompromised patients with COVID-19.

#IDWeek2023 #IDSA #liveevents #covid19 #covid19news #immunocompromised #patientcare #IDweek